These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The search for a cure for Duchenne muscular dystrophy (DMD). Acta Myol; 2005 Dec; 24(3):169-71. PubMed ID: 16629049 [No Abstract] [Full Text] [Related]
5. Function induced modifications of gene expression: an alternative approach to gene therapy of Duchenne muscular dystrophy. Vrbová G J Muscle Res Cell Motil; 2004; 25(2):187-92. PubMed ID: 15360134 [TBL] [Abstract][Full Text] [Related]
7. [Frontline studies on Duchenne muscular dystrophy treatment]. Matsuo M No To Hattatsu; 2009 Mar; 41(2):92-5. PubMed ID: 19517771 [TBL] [Abstract][Full Text] [Related]
8. Duchenne muscular dystrophy and steroids: pharmacologic treatment in the absence of effective gene therapy. Alman BA J Pediatr Orthop; 2005; 25(4):554-6. PubMed ID: 15958914 [No Abstract] [Full Text] [Related]
9. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part III. Ethical considerations. Fardeau M Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S52-4. PubMed ID: 12206796 [TBL] [Abstract][Full Text] [Related]
10. Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies. Le Rumeur E Bosn J Basic Med Sci; 2015 Jul; 15(3):14-20. PubMed ID: 26295289 [TBL] [Abstract][Full Text] [Related]
11. DYS-HAC-iPS cells: the combination of gene and cell therapy to treat duchenne muscular dystrophy. Park IH Mol Ther; 2010 Feb; 18(2):238-40. PubMed ID: 20125163 [No Abstract] [Full Text] [Related]
12. The dystrophy of Duchenne. Jay V; Vajsar J Lancet; 2001 Feb; 357(9255):550-2. PubMed ID: 11229686 [No Abstract] [Full Text] [Related]
13. [Development of novel therapeutic approaches for Duchenne muscular dystrophy]. Takeshima Y No To Hattatsu; 2014 Mar; 46(2):109-14. PubMed ID: 24738186 [No Abstract] [Full Text] [Related]
14. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Takeshima Y; Wada H; Yagi M; Ishikawa Y; Ishikawa Y; Minami R; Nakamura H; Matsuo M Brain Dev; 2001 Dec; 23(8):788-90. PubMed ID: 11720794 [No Abstract] [Full Text] [Related]
15. Recent developments in Duchenne muscular dystrophy: facts and numbers. Walter MC; Reilich P J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):681-685. PubMed ID: 29076660 [No Abstract] [Full Text] [Related]
16. The role of immunosuppression in gene- and cell-based treatments for duchenne muscular dystrophy. Arruda VR Mol Ther; 2007 Jun; 15(6):1040-1. PubMed ID: 17510638 [No Abstract] [Full Text] [Related]
17. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. Nowak KJ; Davies KE EMBO Rep; 2004 Sep; 5(9):872-6. PubMed ID: 15470384 [TBL] [Abstract][Full Text] [Related]
18. Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy. Wells DJ; Ferrer A; Wells KE Expert Rev Mol Med; 2002 Nov; 4(23):1-23. PubMed ID: 14585159 [TBL] [Abstract][Full Text] [Related]
19. Exon Skipping Therapy. Young CS; Pyle AD Cell; 2016 Nov; 167(5):1144. PubMed ID: 27863231 [TBL] [Abstract][Full Text] [Related]
20. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Aartsma-Rus A; van Ommen GJ Lancet Neurol; 2009 Oct; 8(10):873-5. PubMed ID: 19713153 [No Abstract] [Full Text] [Related] [Next] [New Search]